Earnings call transcript: Vext Science posts stronger margins in Q2 2026

Vext Science's second-quarter earnings call revealed stronger profitability despite a revenue decline of 10% year-over-year. The company's gross margin expanded to 55% from 36% a year earlier, driven by increased retail sales, improved cultivation yields, and favorable biological asset adjustments in Ohio. Net loss narrowed to $0.3 million, signaling progress toward break-even.

Revenue came in at $12.1 million, falling short of expectations by $2.22 million, or 15.5%. The shortfall was partially offset by improved margins and a reduced net loss. The company's focus remains on growing Ohio operations, concluding the Arizona repositioning, and paying down debt. Executives anticipate Ohio to remain the primary growth driver, with six dispensaries already open, a seventh under construction, and an eighth expected soon.

The company also expects to complete the Az inventory sales by Q4, marking its first "clean quarter" without inventory-related costs. Management emphasized disciplined sourcing, pricing, and merchandising as key to their commodity-driven business model.